 |
29 Products |  |
56 Diseases | | 29 Products |
|
154 Trials |  |
7457 News |  |
| «12...8384858687888990919293...9798» |
- || letrozole / Generic mfg.
New P3 trial: Dual FSH/HCG Trigger in Letrozole Stimulated Intrauterine Insemination Cycles in Women With Unexplained Infertility (clinicaltrials.gov) - Apr 15, 2016
P3, N=108, Completed, Sponsor: Benha University
- Cervidil (dinoprostone) / Ferring
Trial primary completion date: Randomized Controlled Trial: Induction of Labour of Obese Women With Dinoprostone or Single Balloon Catheter (clinicaltrials.gov) - Apr 9, 2016
P=N/A, N=90, Recruiting, Sponsor: Regina Qu'Appelle Health Region
Trial primary completion date: Dec 2015 --> Jun 2016
- |||| Pentasa enema (mesalazine rectal enema) / Ferring, Pentasa (mesalamine) / Ferring, Takeda
Trial primary completion date, Head-to-Head: An Efficacy and Safety Study of PENTASA in Chinese Patients With Left-sided Active Ulcerative Colitis Followed by a 24-Week Open-Label Extension Phase (clinicaltrials.gov) - Apr 7, 2016
P3, N=249, Recruiting, Sponsor: Ferring Pharmaceuticals
Trial primary completion date: Dec 2015 --> Jun 2016 Trial primary completion date: Apr 2016 --> Aug 2016
- ||||| Firmagon (degarelix) / Astellas, Ferring
New P4 trial, Metastases: A Trial to Evaluate Safety of Firmagon (clinicaltrials.gov) - Apr 1, 2016
P4, N=230, Not yet recruiting, Sponsor: Ferring Pharmaceuticals
- Cervidil (dinoprostone) / Ferring
Phase classification: CYTOPRO: Comparison Between 25 (clinicaltrials.gov) - Mar 25, 2016
P3, N=1700, Completed, Sponsor: University Hospital, Toulouse
Trial primary completion date: Apr 2016 --> Aug 2016 Phase classification: P2 --> P3
- | Glypressin (terlipressin) / Ferring
New P2 trial, Surgery: Effect of Terlipressin Infusion on Systemic and Hepatic Hemodynamics During Hepatobiliary Surgery (clinicaltrials.gov) - Mar 24, 2016
P2, N=50, Recruiting, Sponsor: Assiut University
- Cimzia (certolizumab pegol) / Astellas, UCB
New trial: Lipids, Inflammation, and CV Risk in RA (clinicaltrials.gov) - Mar 22, 2016
P=N/A, N=75, Not yet recruiting, Sponsor: Brigham and Women's Hospital
- ||| Bimzelx (bimekizumab) / UCB, Cimzia (certolizumab pegol) / Astellas, UCB
Clinical: Multiple Dose Study of UCB4940 as add-on to Certolizumab Pegol in Subjects With Rheumatoid Arthritis (clinicaltrials.gov) - Mar 18, 2016
P2, N=102, Recruiting, Sponsor: UCB Celltech
Phase classification: P2 --> P3 N=180 --> 102 | Trial primary completion date: Jun 2017 --> Dec 2016
- || Kepivance (palifermin) / SOBI, Amgen, Firmagon (degarelix) / Astellas, Ferring
Trial primary completion date: Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation (clinicaltrials.gov) - Mar 16, 2016
P2, N=120, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
N=180 --> 102 | Trial primary completion date: Jun 2017 --> Dec 2016 Trial primary completion date: Dec 2016 --> Dec 2017
- Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment closed, Enrollment change: Cimzia Versus Mesalamine for Crohn's Recurrence (clinicaltrials.gov) - Mar 16, 2016
P4, N=10, Active, not recruiting, Sponsor: Milton S. Hershey Medical Center
Trial primary completion date: Dec 2016 --> Dec 2017 Recruiting --> Active, not recruiting | N=24 --> 10
- Cimzia (certolizumab pegol) / Astellas, UCB
Trial primary completion date: CRIB: A Multicener, Postmarketing Study Evaluating the Transfer of Cimzia From the Mother to the Infant Via the Placenta (clinicaltrials.gov) - Mar 15, 2016
P1, N=20, Recruiting, Sponsor: UCB BIOSCIENCES, Inc.
Recruiting --> Active, not recruiting | N=24 --> 10 Trial primary completion date: Apr 2016 --> Nov 2016
- ||| Bimzelx (bimekizumab) / UCB, Cimzia (certolizumab pegol) / Astellas, UCB
Clinical: Multiple Dose Study of UCB4940 as add-on to Certolizumab Pegol in Subjects With Rheumatoid Arthritis (clinicaltrials.gov) - Mar 15, 2016
P2, N=180, Recruiting, Sponsor: UCB Celltech
Trial primary completion date: Apr 2016 --> Nov 2016 N=102 --> 180 | Trial primary completion date: Dec 2016 --> Jun 2017
- Cimzia (certolizumab pegol) / Astellas, UCB
Trial primary completion date, Combination therapy, Metastases: Certolizumab in Combination With Chemotherapy for Patients With Stage IV Lung Adenocarcinomas (clinicaltrials.gov) - Mar 11, 2016
P1, N=34, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
N=102 --> 180 | Trial primary completion date: Dec 2016 --> Jun 2017 Trial primary completion date: Apr 2016 --> Apr 2017
- || Firmagon (degarelix) / Astellas, Ferring, Yervoy (ipilimumab) / BMS
Trial primary completion date, Metastases: Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical Prostatectomy (clinicaltrials.gov) - Mar 11, 2016
P2, N=53, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial primary completion date: Apr 2016 --> Apr 2017 Trial primary completion date: Dec 2016 --> Dec 2017
- | Suprefact (buserelin acetate) / Sanofi, Firmagon (degarelix) / Astellas, Ferring
Enrollment closed: Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer (clinicaltrials.gov) - Mar 9, 2016
P3, N=1538, Active, not recruiting, Sponsor: Radiation Therapy Oncology Group
Trial primary completion date: Dec 2016 --> Dec 2017 Recruiting --> Active, not recruiting
- Xtandi (enzalutamide capsule) / Pfizer, Astellas, Mekinist (trametinib) / Novartis, BeiGene, Firmagon (degarelix) / Astellas, Ferring
Trial primary completion date: Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer (clinicaltrials.gov) - Mar 7, 2016
P2, N=45, Recruiting, Sponsor: Jonsson Comprehensive Cancer Center
Recruiting --> Active, not recruiting Trial primary completion date: May 2016 --> May 2017
- |||||| Firmagon (degarelix) / Astellas, Ferring
Enrollment open, Adverse events, Metastases: PRONOUNCE: A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease (clinicaltrials.gov) - Mar 4, 2016
P3, N=900, Recruiting, Sponsor: Ferring Pharmaceuticals
Trial primary completion date: May 2016 --> May 2017 Not yet recruiting --> Recruiting
- Firmagon (degarelix) / Astellas, Ferring
Trial primary completion date, PARP Biomarker: Androgen Deprivation Therapy Prior to Prostatectomy for Patients with Intermediate and High Risk Prostate Cancer (clinicaltrials.gov) - Mar 2, 2016
P=N/A, N=41, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Not yet recruiting --> Recruiting Trial primary completion date: Feb 2016 --> Feb 2017
- Biomarker, Enrollment change, Trial primary completion date: RA-BioStop: Ultrasound and Withdrawal of Biological DMARDs in Rheumatoid Arthritis (clinicaltrials.gov) - Feb 26, 2016
P4, N=110, Recruiting, Sponsor: Medical University of Graz
Trial primary completion date: Feb 2016 --> Feb 2017 N=68 --> 110 | Trial primary completion date: Jun 2016 --> Jul 2017
- | Glypressin (terlipressin) / Ferring
Trial completion, Trial primary completion date: Terlipressin in Septic Shock in Cirrhosis (clinicaltrials.gov) - Feb 24, 2016
P2/3, N=72, Completed, Sponsor: Hospital Clinic of Barcelona
N=68 --> 110 | Trial primary completion date: Jun 2016 --> Jul 2017 Recruiting --> Completed | Trial primary completion date: Oct 2009 --> Dec 2012
- || Yonsa (abiraterone acetate) / Sun Pharma
Trial primary completion date: NCI-2018-01856: Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer (clinicaltrials.gov) - Feb 23, 2016
P2, N=200, Recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Completed | Trial primary completion date: Oct 2009 --> Dec 2012 Trial primary completion date: Feb 2017 --> Feb 2018
- Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment change, Trial termination, Trial primary completion date: EUS Evaluation of Perianal and Peri-rectal Fistulizing Crohn's Disease With CERTOLIZUMAB Treatment (clinicaltrials.gov) - Feb 21, 2016
P4, N=1, Terminated, Sponsor: Baylor College of Medicine
Trial primary completion date: Feb 2017 --> Feb 2018 N=20 --> 1 | Recruiting --> Terminated | Trial primary completion date: Dec 2013 --> Mar 2014; Not enough subjects to reach accrual goals.
- ||||||| Cimzia (certolizumab pegol) / Astellas, UCB
Trial completion, Trial primary completion date, Combination therapy: A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-na (clinicaltrials.gov) - Feb 17, 2016
P3, N=880, Completed, Sponsor: UCB Pharma SA
N=20 --> 1 | Recruiting --> Terminated | Trial primary completion date: Dec 2013 --> Mar 2014; Not enough subjects to reach accrual goals. Active, not recruiting --> Completed | Trial primary completion date: Jul 2015 --> Jul 2014
- || Cervidil (dinoprostone) / Ferring
New P3 trial: Stepwise Labor Induction Following Failure of Prostaglandin Vaginal Insert for Labor Induction (clinicaltrials.gov) - Feb 17, 2016
P3, N=320, Not yet recruiting, Sponsor: Tel-Aviv Sourasky Medical Center
- || Firmagon (degarelix) / Astellas, Ferring
Trial primary completion date: 3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy (clinicaltrials.gov) - Feb 12, 2016
P2, N=120, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Active, not recruiting --> Completed | Trial primary completion date: Jul 2015 --> Jul 2014 Trial primary completion date: Oct 2016 --> Oct 2017
- |||| Cimzia (certolizumab pegol) / Astellas, UCB
Trial completion: Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate (clinicaltrials.gov) - Feb 10, 2016
P4, N=916, Completed, Sponsor: UCB Pharma SA
Trial primary completion date: Oct 2016 --> Oct 2017 Active, not recruiting --> Completed
- Firmagon (degarelix) / Astellas, Ferring
Enrollment change: Degarelix Acetate Before and During Radiation Therapy in Treating Patients With Prostate Cancer (clinicaltrials.gov) - Feb 3, 2016
P=N/A, N=25, Recruiting, Sponsor: University of Washington
Active, not recruiting --> Completed N=20 --> 25
- | Adstiladrin (nadofaragene firadenovec-vncg) / Ferring
Trial completion: Intravesical Administration of rAd-IFN/Syn3 in Patients With BCG-Refractory or Relapsed Bladder Cancer (clinicaltrials.gov) - Feb 3, 2016
P2, N=40, Completed, Sponsor: FKD Therapies Oy
N=20 --> 25 Active, not recruiting --> Completed
- Menopur (menotropin) / Ferring
Trial primary completion date: HRT Versus MOS for Endometrial Preparation Prior to FET in PCOS Patients (clinicaltrials.gov) - Feb 2, 2016
P4, N=150, Recruiting, Sponsor: Mansoura University
Active, not recruiting --> Completed Trial primary completion date: Aug 2015 --> Feb 2016
- Euflexxa (hyaluronic acid) / Ferring
New trial, HEOR: Comparative Effectiveness of Hyaluronic Acid Injections for Management of Knee Osteoarthritis (clinicaltrials.gov) - Feb 2, 2016
P=N/A, N=20000, Not yet recruiting, Sponsor: University of Arkansas
- |||| Cimzia (certolizumab pegol) / Astellas, UCB
Trial primary completion date: Open-label, Extension Study of CDP870 in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Jan 30, 2016
P3, N=100, Active, not recruiting, Sponsor: Korea Otsuka Pharmaceutical Co.,Ltd.
Trial primary completion date: Aug 2015 --> Feb 2016 Trial primary completion date: Oct 2015 --> Jun 2016
- |||||||||| Firmagon (degarelix) / Astellas, Ferring
New P3 trial, Adverse events, Metastases: PRONOUNCE: A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease (clinicaltrials.gov) - Jan 26, 2016
P3, N=900, Not yet recruiting, Sponsor: Ferring Pharmaceuticals
- ||||| Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment closed: RAPID-C: A Study of Certolizumab Pegol as Additional Therapy in Chinese Patients With Active Rheumatoid Arthritis (clinicaltrials.gov) - Jan 20, 2016
P3, N=431, Active, not recruiting, Sponsor: UCB Pharma SA, Belgium
Trial primary completion date: Oct 2015 --> Jun 2016 Recruiting --> Active, not recruiting
- | Cimzia (certolizumab pegol) / Astellas, UCB
Trial completion: CRADLE: A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia (clinicaltrials.gov) - Jan 20, 2016
P1, N=17, Completed, Sponsor: UCB BIOSCIENCES, Inc.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Firmagon (degarelix) / Astellas, Ferring
Trial primary completion date: Feasibility and Toxicity of Degarelix for Prostate Downsizing Prior to Permanent Seed Prostate Brachytherapy (clinicaltrials.gov) - Jan 17, 2016
P2, N=50, Recruiting, Sponsor: British Columbia Cancer Agency
Active, not recruiting --> Completed Trial primary completion date: Dec 2015 --> Mar 2016
- |||| Orencia (abatacept) / BMS, Actemra IV (tocilizumab) / Roche, JW Pharma
Enrollment open: MAZERATI: Mechanistic Studies of B- and T-Cell Function in RA Patients Treated With TNF Antagonists, Tocilizumab, or Abatacept (clinicaltrials.gov) - Jan 15, 2016
P4, N=90, Recruiting, Sponsor: University of Pittsburgh
Trial primary completion date: Dec 2015 --> Mar 2016 Not yet recruiting --> Recruiting
- ||||| Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment closed: CIMPACT: Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO) (clinicaltrials.gov) - Jan 15, 2016
P3, N=559, Active, not recruiting, Sponsor: UCB Biopharma S.P.R.L.
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Cervidil (dinoprostone) / Ferring
New trial: BALLODINO: Comparing the Efficiency of Cervical Ripening BALLoon (Cook) to the DINOprostone (Propess) for the Cervical Maturation in Case of Unfavorable Cervix (Bishop = 30 kg/m (clinicaltrials.gov) - Jan 11, 2016
P=N/A, N=240, Not yet recruiting, Sponsor: Centre Hospitalier Departemental Vendee
- Cervidil (dinoprostone) / Ferring
Enrollment open: Concurrent Oxytocin With Membrane Sweeping Versus Dinoprostone Pessary in Labor Induction of Multiparous Women at Term (clinicaltrials.gov) - Dec 30, 2015
P=N/A, N=154, Recruiting, Sponsor: Seoul National University Hospital
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | Euflexxa (hyaluronic acid) / Ferring
New P4 trial: The Influence of Hyaluronic Acid Injection Following Knee Arthroscopy (clinicaltrials.gov) - Dec 29, 2015
P4, N=60, Not yet recruiting, Sponsor: Ziv Medical Center
- | Rebyota (fecal microbiota, live-jslm) / Ferring
Enrollment open: PediFETCh: Pediatric FEcal Microbiota Transplant for Ulcerative Colitis (clinicaltrials.gov) - Dec 24, 2015
P0, N=50, Recruiting, Sponsor: McMaster Children's Hospital
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Trial primary completion date: May 2016 --> Nov 2016 | Not yet recruiting --> Recruiting
- cyclophosphamide / Generic mfg.
Enrollment closed, Trial primary completion date, IO biomarker: A Neoadjuvant Study of Androgen Ablation Combined With Cyclophosphamide and GVAX Vaccine for Localized Prostate Cancer (clinicaltrials.gov) - Dec 23, 2015
P1/2, N=29, Active, not recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Not yet recruiting --> Recruiting | Trial primary completion date: May 2016 --> Nov 2016 | Not yet recruiting --> Recruiting Completed --> Active, not recruiting | Trial primary completion date: Apr 2015 --> Apr 2018
- Firmagon (degarelix) / Astellas, Ferring
Trial completion: Degarelix Neo-Adjuvant Radical Prostatectomy Trial (clinicaltrials.gov) - Dec 23, 2015
P2, N=35, Completed, Sponsor: University Health Network, Toronto
Completed --> Active, not recruiting | Trial primary completion date: Apr 2015 --> Apr 2018 Active, not recruiting --> Completed
- Bravelle (urofollitropin) / Ferring
Enrollment open, Trial primary completion date: GnRHa Combined With hCG and hMG for Treatment of Patients With Non-obstructive Azoospermia (clinicaltrials.gov) - Dec 22, 2015
P2, N=30, Recruiting, Sponsor: Jinling Hospital, China
Active, not recruiting --> Completed Not yet recruiting --> Recruiting | Trial primary completion date: Oct 2016 --> Dec 2017
- |||||| Firmagon (degarelix) / Astellas, Ferring
Enrollment open: A Trial Evaluating Two Subcutaneous Injection Techniques and Intramuscular Administration of Degarelix in Patients With Prostate Cancer (clinicaltrials.gov) - Dec 14, 2015
P3, N=120, Recruiting, Sponsor: Ferring Pharmaceuticals
Not yet recruiting --> Recruiting | Trial primary completion date: Oct 2016 --> Dec 2017 Not yet recruiting --> Recruiting
- | Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment open, Trial initiation date: Pilot Study Evaluating the Efficacy of Certolizumab Pegol for Interstitial Cystitis (clinicaltrials.gov) - Dec 14, 2015
P3, N=30, Recruiting, Sponsor: ICStudy, LLC
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Initiation date: Jul 2015 --> Dec 2015
- Firmagon (degarelix) / Astellas, Ferring
Enrollment closed, Enrollment change, PARP Biomarker: Androgen Deprivation Therapy Prior to Prostatectomy for Patients with Intermediate and High Risk Prostate Cancer (clinicaltrials.gov) - Dec 12, 2015
P=N/A, N=41, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Not yet recruiting --> Recruiting | Initiation date: Jul 2015 --> Dec 2015 Recruiting --> Active, not recruiting | N=60 --> 41
- ||| Rekovelle (follitropin delta) / Ferring
Enrollment closed: A Dose-response Trial Using FE 999049 in Japanese Women Undergoing in Vitro Fertilisation (IVF) / Intracytoplasmic Sperm Injection (ICSI) Treatment (clinicaltrials.gov) - Dec 11, 2015
P2, N=159, Active, not recruiting, Sponsor: Ferring Pharmaceuticals
Recruiting --> Active, not recruiting | N=60 --> 41 Recruiting --> Active, not recruiting
- Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment closed: CRADLE: A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia (clinicaltrials.gov) - Dec 5, 2015
P1, N=17, Active, not recruiting, Sponsor: UCB BIOSCIENCES, Inc.
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- |||| Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment status: RAPID-C OLE: An Open-label Extension Study of Certolizumab Pegol in Chinese Patients With Rheumatoid Arthritis Who Enrolled in RA0044 (clinicaltrials.gov) - Dec 5, 2015
P3, N=320, Enrolling by invitation, Sponsor: UCB Pharma SA
Recruiting --> Active, not recruiting Recruiting --> Enrolling by invitation